Jubilant Ingrevia reported a 41% year-on-year rise in net profit to Rs 106 crore for Q1FY27, driven by improved volumes and better pricing across its segments. The company also saw a 25% increase in net sales to Rs 1,300 crore.
Detailed Coverage
Jubilant Ingrevia Q1FY27 Results: Profit Surges 41% to Rs 106 Crore
Net Profit: Rs 106 crore (up 41% YoY) Net Sales: Rs 1,300 crore (up 25% YoY) Reader Takeaway: Strong profit growth driven by volume recovery and better pricing, with expansion projects on track. ## What just happened Jubilant Ingrevia announced its financial results for the first quarter of Fiscal Year 2027 (Q1FY27). The company reported a significant year-on-year increase in net profit, which grew by 41% to Rs 106 crore. This growth was supported by a 25% rise in net sales, reaching Rs 1,300 crore, driven by volume recovery and improved pricing across its business segments. ## Why this matters The strong quarterly performance indicates operational efficiency and successful market strategies. The growth in net profit and sales signals a positive trajectory for the company, which is beneficial for shareholders. The company's maintained EBITDA guidance for FY27 provides confidence in its future performance. ## The backstory Jubilant Ingrevia, a global integrated life science ingredients and solutions provider, operates across three key business segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The company has been focusing on expanding its capacity and R&D capabilities. ## What changes now The company is focused on operational efficiencies, targeting Rs 100 crore in lean savings for FY27. Key projects like the Multi-Purpose Plant (MPP) at Gajraula are on schedule for commissioning by year-end. Expansion in R&D for semiconductor opportunities is also underway. ## Risks to watch While the outlook is positive, investors should monitor the progress of ongoing expansion projects and the successful integration of new capacities. Any delays or cost overruns could impact future profitability. ## Peer comparison (No peer comparison data available in the filing.) ## Context metrics (time-bound) * **Net Sales:** Rs 1,300 crore (Q1FY27), up 25% YoY. * **EBITDA:** Rs 199 crore (Q1FY27), up 40% YoY. * **EBITDA Margin:** 15.3% (Q1FY27). * **Net Profit:** Rs 106 crore (Q1FY27), up 41% YoY. * **EPS:** Rs 6.7 (Q1FY27). * **Specialty Chemicals Revenue:** Rs 533 crore, EBITDA Rs 139 crore, Margin 26%. * **Nutrition & Health Solutions Revenue:** Rs 243 crore, EBITDA Rs 36 crore, Margin 15%. * **Chemical Intermediates Revenue:** Rs 524 crore, EBITDA Rs 57 crore, Margin 11% (EBITDA grew 240% YoY). * **FY27 EBITDA Guidance:** Rs 750-800 crore. * **FY27 Lean Savings Target:** Rs 100 crore. ## What to track next Investors will be keen to observe the commissioning of the MPP at Gajraula and the development of its R&D pipeline for semiconductor opportunities. Continued performance in specialty chemicals and nutrition segments will be key indicators.
